Woburn, MA — CryoXtract Instruments, LLC, a leader in developing unique automation solutions for preserving and optimizing frozen biological samples, announced that it entered into an agreement with Bio-Strategy Ltd. to distribute its CXT 750 Automated Frozen Sample Aliquotter and CXT 350 Frozen Sample Aliquotter solutions in Australia and New Zealand. Bio-Strategy is a leading distributor in the Australasian market, representing some of the most innovative technology brands for research, biotechnology and clinical diagnostic applications. In particular, the company specializes in representing industry leaders in genomics and pathology. Both areas of research are expected to meaningfully benefit from integrating CryoXtract’s products into their workflows to optimize laboratory efficiency and scientific outcomes.

The agreement is part of a global expansion launched by CryoXtract this year, as the company rolled out its award-winning CXT 750 Automated Frozen Sample Aliquotter and recently introduced a benchtop model, the CXT 350 Frozen Sample Aliquotter. Both systems offer the most effective and efficient automated solution for the repeated aliquotting of frozen biosamples. The partnership with Bio-Strategy marks CryoXtract’s first entrée into Asia-Pacific, a region that is expected to have one of the highest global growth rates for biosample collections in coming years. Earlier this year, CryoXtract introduced its products to the Benelux countries and Germany through an exclusive distribution agreement with GC biotech B.V.

“Bio-Strategy has strong relationships with major research institutions and biorepositories in Australia and New Zealand, which will provide CryoXtract with the opportunity to rapidly and efficiently introduce our products to leading scientists and most effectively service this market,” said John A. McCarthy, Jr., CryoXtract’s Chief Executive Officer.

CryoXtract’s frozen sample aliquotting solutions support a widespread need for targeted, repeated and safe access to frozen biosamples, which are critical to the advancement of molecular medicine, biomarker discovery/validation and other important R&D initiatives. The company’s products allow for uniform and efficient distribution of frozen tissue and biofluid aliquots, while maximizing sample integrity and optimizing scientific outcomes. The CXT 750 and benchtop CXT 350 models offer unprecedented access to stored samples while maintaining their frozen state, ensuring the quality of both the primary and aliquotted sample, and eliminating their potential degradation due to thawing.

“I was very impressed with CryoXtract’s new CXT 350 when I saw it for the first time at the International Society for Biological and Environmental Repositories (ISBER 2013) meeting in Sydney earlier this year,” said Robert Lyon, Bio-Strategy’s Director of Sales & Marketing. “Bio-Strategy specializes in identifying and delivering the best leading-edge technology solutions available to researchers and clinicians in Australia and New Zealand, so we are excited to be working with CryoXtract to introduce their innovative automated biosampling instruments to our markets.”

CryoXtract, based in Woburn, Massachusetts, is a subsidiary of private investment company Allied Minds, Inc.

“CryoXtract’s products offer a unique value proposition to the scientific community because of their ability to improve both the efficiency of laboratory workflows and the quality of the samples being used in research,” said Dr. Omar Amirana, Managing Director and Head of Life Sciences at Allied Minds. “We are pleased to have this set of innovative solutions in our portfolio of cutting-edge life-sciences technologies.”

About CryoXtract Instruments, LLC

CryoXtract develops and commercializes unique automation solutions that allow for the retrieval of multiple frozen samples from a single frozen biosample without exposing the source sample to the deleterious biological impact from freeze/thaw cycling. The Company’s novel automation technology platform improves frozen biosample processing, protects the viability of frozen biosamples after cores have been extracted, improves lab efficiencies and economics, and results in better scientific outcomes. In May 2012, the International Society for Biological and Environmental Biorepositories (ISBER) awarded its prestigious Outstanding New Product Award to the Company’s CXT 750 Frozen Sample Aliquotter.

About Bio-Strategy Ltd.

Bio-Strategy Ltd. supplies specialist scientific instrumentation, equipment and consumables to the scientific and diagnostic markets in Australia, New Zealand and the South Pacific. The company offers sales, applications support and technical service for all their products. The company’s key agencies include Thermo One Lambda Inc., Siemens (Molecular and Microbiology), Hamilton Company, Hamilton Robotics, Molecular Devices, Nanostring, Qiagen (NZ Only), Leica (NZ only), Priorclave, UVP, and Kaltis.